Latest Biotech News

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

Ecofibre Limited reported a $2.2 million operating cash outflow in 3Q25 with total cash at $1.3 million, highlighting mixed progress across its business units and a pressing need to monetise assets to sustain operations.

Opyl Limited reports strong progress in AI-driven clinical trial optimisation with active commercial initiatives, strategic partnerships, and a planned capital raise to support growth amid tight cash reserves.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.

Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.